- Home
- KPRX vs SNGX Comparison
KPRX vs SNGX Comparison
Compare KPRX & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- SNGX
- Stock Information
- Founded
- KPRX 1998
- SNGX 1987
- Country
- KPRX United States
- SNGX United States
- Employees
- KPRX N/A
- SNGX N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- KPRX Health Care
- SNGX Health Care
- Exchange
- KPRX Nasdaq
- SNGX Nasdaq
- Market Cap
- KPRX 9.2M
- SNGX 10.1M
- IPO Year
- KPRX N/A
- SNGX 1987
- Fundamental
- Price
- KPRX $2.65
- SNGX $2.79
- Analyst Decision
- KPRX Strong Buy
- SNGX Strong Buy
- Analyst Count
- KPRX 1
- SNGX 1
- Target Price
- KPRX $10.00
- SNGX $6.00
- AVG Volume (30 Days)
- KPRX 32.4K
- SNGX 871.1K
- Earning Date
- KPRX 11-07-2025
- SNGX 11-07-2025
- Dividend Yield
- KPRX N/A
- SNGX N/A
- EPS Growth
- KPRX N/A
- SNGX N/A
- EPS
- KPRX N/A
- SNGX N/A
- Revenue
- KPRX N/A
- SNGX N/A
- Revenue This Year
- KPRX N/A
- SNGX N/A
- Revenue Next Year
- KPRX N/A
- SNGX N/A
- P/E Ratio
- KPRX N/A
- SNGX N/A
- Revenue Growth
- KPRX N/A
- SNGX N/A
- 52 Week Low
- KPRX $2.25
- SNGX $1.09
- 52 Week High
- KPRX $4.18
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- KPRX 46.53
- SNGX 49.04
- Support Level
- KPRX $2.60
- SNGX $2.58
- Resistance Level
- KPRX $2.80
- SNGX $2.98
- Average True Range (ATR)
- KPRX 0.11
- SNGX 0.20
- MACD
- KPRX -0.01
- SNGX -0.08
- Stochastic Oscillator
- KPRX 21.21
- SNGX 32.81
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).